Kearns-Sayre syndrome (KSS) is a rare mitochondrial disorder that affects roughly 1 to 3 per 100,000 people worldwide. It develops before age 20 and progressively damages the muscles that move the eyes, the light-sensing tissue at the back of the eye, and the electrical system of the heart. Because mitochondria supply energy to nearly every cell in the body, the syndrome can ripple outward to affect the brain, the endocrine system, hearing, and growth.
The Three Defining Features
KSS is diagnosed when three features appear together: onset before age 20, progressive paralysis of the muscles around the eyes, and a distinctive pigment change in the retina. The eye muscle paralysis, known as chronic progressive external ophthalmoplegia (CPEO), usually shows up first. Eyelids droop, and the eyes gradually lose the ability to move in certain directions. It tends to affect both eyes symmetrically, so people sometimes don’t notice double vision, but the drooping lids and limited eye movement become increasingly obvious.
The retinal changes involve an abnormal salt-and-pepper pattern of pigment across the back of the eye. This pigmentary retinopathy can reduce night vision or cause subtle visual field loss, though it doesn’t always progress to severe vision impairment. An eye exam with a dilated pupil is typically how a clinician spots it.
The third hallmark, cardiac conduction defects, is the most dangerous. The heart’s electrical signals slow or become blocked, sometimes progressing from mild delays to complete heart block, where the upper and lower chambers of the heart beat independently. In a case series of 35 patients, all four deaths during the study period were caused by sudden cardiac events. That finding underscores why heart monitoring is central to managing this condition.
What Goes Wrong Inside the Cell
The root cause is a large deletion in mitochondrial DNA. Normal mitochondrial DNA is a small circular molecule that encodes the proteins your cells need to convert food into usable energy. In KSS, a chunk of that DNA, anywhere from about 1,100 to 10,000 base pairs, is missing. The most common deletion removes 4,977 base pairs and is sometimes called the “common deletion.”
These deletions knock out genes for transfer RNA molecules, which are essential for building proteins inside the mitochondria. Without those transfer RNAs, the cell can’t assemble key components of the energy-production chain. Larger deletions may also remove the instructions for building parts of the chain directly. Either way, the result is the same: cells that need a lot of energy, like heart muscle, skeletal muscle, and brain cells, start to malfunction because they can’t produce enough of it.
Most cases arise from a new, spontaneous deletion rather than being inherited from a parent. The deletion occurs in some mitochondria but not others within the same cell, a situation called heteroplasmy. Tissues that end up with a higher proportion of damaged mitochondria are the ones that develop symptoms.
Symptoms Beyond the Eyes and Heart
In addition to the defining triad, a person with KSS must have at least one additional feature for a formal diagnosis. These can include:
- Cerebellar ataxia: difficulty with coordination and balance, leading to an unsteady gait
- Short stature: growth hormone disruption can limit height during childhood and adolescence
- Hearing loss: sensorineural deafness that may develop gradually
- Cognitive decline: ranging from learning difficulties in children to dementia in adults
- Endocrine problems: diabetes, thyroid dysfunction, or delayed puberty can emerge as affected glands lose energy capacity
The mix of symptoms varies widely from person to person, even among those carrying the same deletion. That variability is largely driven by how many defective mitochondria end up in each tissue.
How KSS Is Diagnosed
Diagnosis often lags behind symptom onset by several years. In one case series, the average age when symptoms first appeared was 17, but the average age at diagnosis was 26. Part of the delay comes from the rarity of the condition and part from its gradual onset; drooping eyelids and mild coordination trouble don’t always trigger an urgent workup.
When KSS is suspected, several tests help confirm it. An electrocardiogram checks for conduction delays in the heart. A spinal tap may reveal elevated protein in the cerebrospinal fluid (above 100 mg/dL) or low folate levels in the brain, both of which are common in KSS. A muscle biopsy can show “ragged-red fibers,” a distinctive pattern under the microscope where damaged mitochondria cluster abnormally at the edges of muscle cells. The definitive confirmation comes from genetic testing of muscle tissue or blood, which identifies the specific mitochondrial DNA deletion.
Cardiac Monitoring and Pacemakers
Heart block is the leading cause of death in KSS, and it can progress rapidly. Patients with even mild conduction delays on an electrocardiogram, such as a bundle branch block or fascicular block, face a meaningful risk of advancing to complete heart block. In one review, the mortality rate for patients who developed ventricular conduction defects was 20%.
Because of that rapid progression, the threshold for placing a permanent pacemaker is low. Clinicians often recommend a pacemaker prophylactically, meaning before complete heart block develops, rather than waiting for a crisis. Regular electrocardiograms, sometimes supplemented with longer-term heart rhythm monitors, are a standard part of ongoing care.
Managing Energy and Nutrition
There is no cure for KSS, and no treatment reverses the underlying mitochondrial DNA deletion. Management focuses on supporting the body’s remaining energy-production capacity and treating complications as they arise.
Coenzyme Q10, a molecule that shuttles electrons within the mitochondrial energy chain, is commonly supplemented to try to boost whatever residual function remains. Folinic acid, a form of folate that crosses into the brain more readily, has shown promise for correcting the cerebral folate deficiency that often accompanies KSS. In a follow-up study of patients treated with folinic acid for one to eight years, all who underwent repeat spinal taps showed complete normalization of their previously low brain folate levels, and two patients experienced neurological improvement. No adverse effects were observed, though the disease continued to progress in most participants.
Endocrine problems are managed individually: hormone replacement for thyroid dysfunction, insulin for diabetes, growth hormone for children with significant short stature. Hearing aids or cochlear implants may help those with progressive hearing loss.
Long-Term Outlook
Older medical literature often described KSS as fatal in early adulthood, but more recent data paints a somewhat more nuanced picture. In a case series tracking 35 patients over an average of nearly 11 years, only 11% died during the study period, and the mean age at death was 46. The authors noted that, contrary to common belief, most patients lived beyond middle adulthood. That said, all deaths were sudden cardiac events, reinforcing the importance of proactive heart monitoring and early pacemaker placement.
The pace of progression varies. Some people maintain functional independence for decades with appropriate cardiac care and symptom management, while others experience significant neurological or muscular decline during adolescence. Because the syndrome touches so many organ systems, care typically involves a team spanning cardiology, ophthalmology, endocrinology, and neurology, with the specific mix depending on which symptoms dominate.